Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 3/20 | 0.43 |
| ▸ | KDR | P35968 | 3/20 | 0.43 |
| ▸ | MAPT | P10636 | 2/20 | 0.43 |
| ▸ | NR2E1 | Q9Y466 | 6/20 | 0.43 |
| ▸ | CSF1R | P07333 | 2/20 | 0.43 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.40 |
| ▸ | RORA | P35398 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | NEK2 | P51955 | 4/20 | 0.38 |
| ▸ | PLK1 | P53350 | 3/20 | 0.38 |
| ▸ | MALT1 | Q9UDY8 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2202608 | 0.92 | CSF1R (0.45) | BRAFKDRMAPTNR2E1CSF1R | |
| SCHEMBL2200252 | 0.90 | MAPT (0.46) | BRAFKDRMAPTNR2E1CSF1R | |
| SCHEMBL2203664 | 0.86 | NR2E1 (0.43) | MAPTNR2E1POLBRORATP53 | |
| SCHEMBL2204009 | 0.86 | ROCK2 (0.45) | BRAFKDRROCK2POLBNEK2 | |
| SCHEMBL2202471 | 0.81 | KDR (0.44) | BRAFKDRMAPTPOLBTP53 | |
| SCHEMBL2203105 | 0.80 | KDR (0.47) | BRAFKDRNR2E1CSF1RROCK2 | |
| SCHEMBL2202443 | 0.79 | NR2E1 (0.70) | NR2E1MALT1 | |
| SCHEMBL2204785 | 0.79 | MAPT (0.38) | MAPTNR2E1POLBRORATP53 | |
| SCHEMBL2200934 | 0.79 | BRAF (0.45) | BRAFKDRCSF1RROCK2NEK2 | |
| SCHEMBL2200310 | 0.78 | NR2E1 (0.45) | BRAFMAPTNR2E1POLBRORA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | claimed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | claimed |
| US-7977338-B2 | Phenylacetamides being FLT3 inhibitors | NOVARTIS AG (CH) | 2011-07-12 | — | — | US | disclosed |
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | NOVARTIS AG (CH) | 2010-03-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100075980-A1 | Phenylacetamides being FLT3 Inhibitors | FLT3, JAK2, ABL1 | BRAF 4/4885KDR 110/4885MAPT 3474/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.